https://european-biotechnology.net/wp-content/uploads/2025/08/IO-Biotech-ASCO-2025-Cover-Image-e1754920785505-1030x581-1.jpg5811030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-08-11 14:00:262025-08-11 19:02:02IO Biotech’s cancer jab falls short in Phase 3, but Danish firm still eyes FDA approval
https://european-biotechnology.net/wp-content/uploads/2025/08/EU-Biotech-Act_1299854022_oynRQWpc8YPprtvb5tO9Tcqvgwp8kDJO-e1754461928206.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-08-06 06:34:072025-08-06 06:34:07EU Biotech Act: Have your say!
https://european-biotechnology.net/wp-content/uploads/2025/08/Ragon-Institute-PM-e1754387379667.png490869Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-08-05 09:50:122025-08-05 09:50:12ReiThera starts study on HIV vaccine
